Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
People
Adjust height of sidebar
KMap
Profile
Junaid Arshad
Assistant Professor, Medicine - (Clinical Scholar Track)
Medicine
Full Page
Overview
Research
More
Collaboration
(19)
Denise Roe
Mutual work: 1 Proposal
Collaboration Details
Rachna Shroff
Mutual work: 15 Grants﹒23 Proposals
Collaboration Details
Juanita Merchant
Mutual work: 4 Proposals
Collaboration Details
Hina Arif Tiwari
Mutual work: 9 Grants﹒11 Proposals
Collaboration Details
Ritu Pandey
Mutual work: 1 Proposal
Collaboration Details
Page 1 of 4
Previous page
Next page
Grants
(15)
A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Tre
Active
·
2024
·
$0 / $548.6K
·
External
Co-Investigator (COI)
oncology,
clinical trials,
chemotherapy,
cancer treatment,
targeted therapy
Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of BI 907828 for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Track Adenoc
Active
·
2024
·
$0 / $462K
·
External
Co-Investigator (COI)
cancer treatment,
clinical trial,
biliary tract adenocarcinoma,
targeted therapy,
precision medicine
A Phase 2a, Double-Blind, Placebo-Controlled, Multi-Center, Randomized Study Evaluating LSTA1 when Added to Standard of Care (SOC) Versus Standard of Care Alone in Subjects with Advanced Solid Tumors
Active
·
2023
·
$0 / $825.5K
·
External
Co-Investigator (COI)
oncology,
clinical trials,
immunotherapy,
cancer treatment,
drug efficacy
A Phase 1 Dose-Escalation Study of FF-10832 for the Treatment of Advanced Solid Tumors and Lymphomas
Active
·
2023
·
$0 / $684.8K
·
External
Co-Investigator (COI)
cancer treatment,
drug trial,
dose escalation,
solid tumors,
lymphomas
Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)
Active
·
2023
·
$0 / $568.2K
·
External
Co-Investigator (COI)
colorectal cancer,
treatment,
clinical trial,
dkn-01,
chemotherapy
Page 1 of 3
Previous page
Next page
Publications
(21)
Recent
Myeloid-Derived Suppressor Cells: Therapeutic Target for Gastrointestinal Cancers
2024
immunotherapy,
cancer,
myeloid cells,
gastrointestinal,
therapeutic targeting
Biomarker Testing and Role of Tyrosine Kinase Inhibitors and Immunotherapy for Esophageal Squamous Cell Carcinoma
2024
biomarker testing,
tyrosine kinase inhibitors,
immunotherapy,
esophageal squamous cell carcinoma
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline
2023
cancer therapy,
neuroendocrine tumors,
metastatic tumors,
gastroenteropancreatic,
asco guideline
Pan tumor outcomes to immune checkpoint inhibitors in patients of Native American origin in the United States: The multicenter POINT-US study.
2023
immunotherapy,
cancer,
ethnicity,
clinical trial,
treatment response
Liver-Directed Therapy Combined with Systemic Therapy: Current Status and Future Directions
2023
cancer treatment,
combination therapy,
liver cancer,
interventional oncology,
future developments
Outcomes for immuno-chemotherapy based treatment in patients with poorly differentiated extrapulmonary neuroendocrine carcinoma.
2023
immunochemotherapy,
neuroendocrine carcinoma,
treatment outcomes,
poorly differentiated,
extrapulmonary
Friend or foe? Locoregional therapies and immunotherapies in the current hepatocellular treatment landscape
2023
immunotherapy,
hepatocellular,
locoregional therapies,
treatment landscape,
friend or foe
KIT resistance mutations identified by circulating tumor DNA and treatment outcomes in advanced gastrointestinal stromal tumor.
2022
cancer genetics,
treatment outcomes,
circulating tumor dna,
gastrointestinal stromal tumor,
therapeutic resistance
Genomic Landscape of Angiosarcoma: A Targeted and Immunotherapy Biomarker Analysis
2021
genomic,
angiosarcoma,
immunotherapy,
biomarker,
targeted
Immunotherapy strategies for gastrointestinal stromal tumor
2021
immunotherapy,
gastrointestinal,
stromal tumor,
cancer treatment,
therapeutic approaches